Tirzepatide represents a groundbreaking treatment agent for individuals battling type 2 diabetes. As a dual receptor activator, it targets both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic https://shaniavnhm853044.fitnell.com/81561295/tirzepatide-a-novel-glp-1-and-gip-receptor-agonist